Literature DB >> 11349216

Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia.

A Dursun1, A Poyraz, C Sezer, G Akyol.   

Abstract

Several studies have been demonstrated the value of c-ErbB-2 and Bcl-2 in predicting the biological behaviour of tumors. The aim of this study was to investigate Bcl-2 and c-ErbB-2 expression in colorectal carcinomas and the correlation between their presence and other clinicopathologic parameters. Eighty-six colorectal carcinomas and 17 adenomas were stained with Bcl-2 and c-ErbB-2 immunohistochemically. Staining patterns were assessed semi-quantitatively and correlated with tumor size, Duke s classification, tumor differentiation, mucinous characteristic and anatomic locations. We detected Bcl-2 expression in 10 of 17 adenomas (58.8 %) and 31 of 86 carcinomas (36.04 %). Positive staining in normal mucosa was observed only in the compartment of cryptic cells. However neither the difference in the rates of Bcl-2 positivity in adenoma and carcinoma groups, nor the correlation with other mentioned clinicopathological parameters, were found statistically significant. Bcl-2 expression was found to be significantly high in mucinous carcinomas. Expression of c-ErbB-2 was observed in 12 of 86 (13.95 %) carcinomas. It was not detected in adenomas and normal mucosa. Although the incidence of c-ErbB-2 in nonmucinous carcinoma was higher than that of mucinous carcinoma, this was not significant. In addition we were unable to show any significant relation between c-ErbB-2 expression and other clinicopathologic features. Our result suggest that c-ErbB-2 protein expression in colorectal carcinomas, is not very frequent event. There is no correlation between c-ErbB-2 expression and malignant potential of colorectal carcinomas. Higher expressions of Bcl-2 in adenomas than carcinomas suggest us a possible role of Bcl-2 in early carcinogenesis of colon. However since we were unable to find any significant correlation between Bcl-2 expression and other parameters the impact of this gene on biological behavior is still unclear for us.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11349216     DOI: 10.1007/bf03032600

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  15 in total

Review 1.  Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma.

Authors:  U Manne; R B Myers; C Moron; R B Poczatek; S Dillard; H Weiss; D Brown; S Srivastava; W E Grizzle
Journal:  Int J Cancer       Date:  1997-06-20       Impact factor: 7.396

2.  Immunoreactivity of p53, Ki-67, and Bcl-2 in oncocytic adenomas and carcinomas of the thyroid gland.

Authors:  J Müller-Höcker
Journal:  Hum Pathol       Date:  1999-08       Impact factor: 3.466

Review 3.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

4.  Expression of Bcl-2 and p53 in the colorectal adenoma-carcinoma sequence.

Authors:  X P Hao; M Ilyas; I C Talbot
Journal:  Pathobiology       Date:  1997       Impact factor: 4.342

Review 5.  Role of HER2 gene overexpression in breast carcinoma.

Authors:  S Ménard; E Tagliabue; M Campiglio; S M Pupa
Journal:  J Cell Physiol       Date:  2000-02       Impact factor: 6.384

6.  Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance.

Authors:  G B Baretton; J Diebold; G Christoforis; M Vogt; C Müller; K Dopfer; K Schneiderbanger; M Schmidt; U Löhrs
Journal:  Cancer       Date:  1996-01-15       Impact factor: 6.860

7.  Inhibition of apoptosis during development of colorectal cancer.

Authors:  A Bedi; P J Pasricha; A J Akhtar; J P Barber; G C Bedi; F M Giardiello; B A Zehnbauer; S R Hamilton; R J Jones
Journal:  Cancer Res       Date:  1995-05-01       Impact factor: 12.701

8.  Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction.

Authors:  W Gorczyca; M Markiewski; A Kram; T Tuziak; W Domagala
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 9.  Bcl-2 and the regulation of programmed cell death.

Authors:  J C Reed
Journal:  J Cell Biol       Date:  1994-01       Impact factor: 10.539

10.  Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significance.

Authors:  R A Tollenaar; J H van Krieken; H J van Slooten; D J Bruinvels; K M Nelemans; L J van den Broek; J Hermans; J H van Dierendonck
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more
  4 in total

1.  Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients.

Authors:  Jayson Wang; James Hollingshead; Nabil El-Masry; Donna Horncastle; Ian Talbot; Ian Tomlinson; Malcolm R Alison; Mona El-Bahrawy
Journal:  J Gastrointest Cancer       Date:  2012-09

2.  Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.

Authors:  Michael Pohl; I Stricker; A Schoeneck; K Schulmann; S Klein-Scory; I Schwarte-Waldhoff; M Hasmann; A Tannapfel; W Schmiegel; A Reinacher-Schick
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-02       Impact factor: 4.553

3.  Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer.

Authors:  Erik J Blok; Peter Jk Kuppen; Jeroen Em van Leeuwen; Cornelis Fm Sier
Journal:  Clin Med Insights Oncol       Date:  2013-02-21

4.  Multiple regression analysis of mRNA-miRNA associations in colorectal cancer pathway.

Authors:  Fengfeng Wang; S C Cesar Wong; Lawrence W C Chan; William C S Cho; S P Yip; Benjamin Y M Yung
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.